Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-dose glucocorticoids in hyperandrogenism.

Leonardo Rizzo1, Viviana Dobrovsky, Karina Danilowicz

  • 1División Endocrinología, Hospital de Clinicas, y 21 Catedra de Farmacología, Facultad de Medicina, Universidad de Buenos Aires.

Medicina
|July 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Mild autonomic cortisol secretion: comorbidities and surgical treatment outcomes].

Medicina·2025
Same author

Primary empty sella

Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)·2025
Same author

Double pituitary adenoma associated with acromegaly and hyperprolactinemia: a case report.

Archives of endocrinology and metabolism·2025
Same author

Cultural evolution, social ratcheting and the evolution of human division of labour.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2025
Same author

[Sarcopenia: new cut-off value of handgrip in postmenopausal Argentine women].

Medicina·2024
Same author

Depth effect on point shear wave velocity elastography: Evidence in a chronic hepatitis C patient cohort.

Ultrasound (Leeds, England)·2024

Low-dose glucocorticoids effectively normalize androgen and cortisol levels in women with hyperandrogenism, improving clinical signs and potentially aiding fertility. Treatment withdrawal reversed these beneficial effects.

Area of Science:

  • Endocrinology
  • Reproductive Medicine
  • Pharmacology

Background:

  • Hyperandrogenism in women is associated with clinical signs and hormonal imbalances.
  • Glucocorticoids are known to affect the hypothalamic-pituitary-adrenal (HPA) axis and steroidogenesis.
  • The therapeutic potential of low-dose glucocorticoids in managing hyperandrogenism requires further investigation.

Purpose of the Study:

  • To investigate the effect of low-dose glucocorticoids on androgen and cortisol secretion.
  • To evaluate the impact on clinical signs of hyperandrogenism and sex hormone-binding globulin (SHBG).
  • To assess the efficacy and safety of betamethasone and methylprednisolone in hyperandrogenic women.

Main Methods:

  • Two protocols involving low-dose betamethasone or methylprednisolone administered orally once daily.

Related Experiment Videos

  • Evaluation of clinical signs, total, free, and bioavailable testosterone, SHBG, and cortisol levels.
  • Blood samples collected in the follicular phase at morning and evening to assess diurnal variations.

    • Main Results:

    • Significant reduction in morning and evening cortisol and testosterone levels observed in both protocols (p<0.05 to <0.01).
    • Betamethasone showed a more pronounced effect on hormone reduction (p<0.05).
    • Increased morning SHBG levels and improvement in clinical hyperandrogenism were noted with betamethasone; no side effects reported.

    Conclusions:

    • Low-dose glucocorticoids effectively normalize serum androgens and cortisol in hyperandrogenic women.
    • These agents may be beneficial for managing hyperandrogenism, particularly in cases with cycle irregularities or fertility concerns.
    • Therapeutic effects were reversible upon treatment discontinuation, with hormone levels returning to pre-treatment values.